Seoul, South Korea – GoYoung, a leading South Korean semiconductor inspection equipment manufacturer, saw its stock price skyrocket on Monday after securing US Food and Drug Administration (FDA) approval for its neurosurgical robot.

Shares of GoYoung surged 30% to close at 12,220 won on the KOSDAQ market, marking the daily upper limit.

The company announced that its advanced neurosurgical robot, Geniant Cranial, has successfully passed FDA regulatory hurdles, paving the way for its entry into the vast US medical device market.

"With this approval, we can now actively market our neurosurgical robot in the world's largest medical device market, the United States," said a GoYoung spokesperson. "Furthermore, this FDA clearance will also facilitate our expansion into other countries that recognize the FDA's stringent standards."

GoYoung has been making significant strides in diversifying its business beyond semiconductor inspection equipment. The company's foray into the medical device sector, particularly with its innovative neurosurgical robot, highlights its ambition to become a global player in the healthcare technology industry.